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Secretions of the uterus support survival and growth of the
conceptus (embryofetus and associated membranes) during preg-
nancy. Galectin-15, also known as OVGAL11 and a previously
uncharacterized member of the galectin family of secreted -gal-
actoside lectins containing a conserved carbohydrate recognition
domain and a separate putative integrin binding domain, was
discovered in the uterus of sheep. In endometria of cyclic and
pregnant sheep, galectin-15 mRNA was expressed specifically in
the endometrial luminal epithelium but not in the conceptus. In
pregnant sheep, galectin-15 mRNA expression appeared in the
epithelia between days 10 and 12 and increased between days 12
and 16. Progesterone induced and IFN- stimulated galectin-15
mRNA in the endometrial epithelium. Galectin-15 protein was
concentrated near and on the apical surface of the endometrial
luminal epithelia and localized within discrete cytoplasmic crystal-
line structures of conceptus trophectoderm (Tr). In the uterine
lumen, secreted galectin-15 protein increased between days 14 and
16 of pregnancy. Galectin-15 protein was functional in binding
lactose and mannose sugars and immunologically identical to the
unnamed Mr 14,000 (14K) protein from the ovine uterus that forms
crystalline inclusion bodies in endometrial epithelia and conceptus
Tr. Based on the functional studies of other galectins, galectin-15
is hypothesized to function extracellularly to regulate Tr migration
and adhesion to the endometrial epithelium and intracellularly to
regulate Tr cell survival, growth, and differentiation. Galectins may
be useful as cellular and molecular markers for endometrial func-
tion and receptivity, to enhance conceptus survival and develop-
ment, and to evaluate and enhance fertility.
Epithelia of the uterine endometrium synthesize and secreteor selectively transport a variety of substances, collectively
termed histotroph, necessary for conceptus (embryofetus and
associated membranes) survival, growth, and implantation (1–
5). Histotroph is a rather undefined, complex mixture of trans-
port proteins, ions, cytokines, growth factors, lymphokines,
hormones, protease inhibitors, and other molecules (1, 3, 4). In
rodents, colony-stimulating factor one, leukemia inhibitory fac-
tor, and calcitonin are examples of proteins in histotroph that
mediate establishment of uterine receptivity and stimulate con-
ceptus implantation (6–8). In humans, histotroph appears to be
the primary source of nutrition for conceptus development
during the first trimester, when mechanisms for hematotrophic
nutrition are being established (9). Uterine secretions are of
particular importance for conceptus survival and growth in
domestic animals because of their protracted periimplantation
period and noninvasive types of placentation (3, 4, 10). Available
evidence from humans, laboratory animals, and domestic ani-
mals indicates that a reduction in uterine histotroph compro-
mises periimplantation conceptus survival and growth, which
can lead to infertility and intrauterine growth retardation (9, 11,
12). Recent studies correlate inadequate expression of cell-
surface and secretory proteins with retarded endometrial dif-
ferentiation and defective endometrial secretory phases (13–15).
Therefore, identification of useful molecular and cellular mark-
ers of endometrial function and receptivity to the conceptus are
of utmost importance, because they can be used for evaluation,
regulation, and enhancement of fertility (15).
To understand the periimplantation pregnancy defect, the
uterine gland knockout sheep model (11) was used for a gene
expression profiling project using an endometrial cDNA library
from the uterus of day-14 pregnant sheep. Interestingly,1% of
the 5,000 ESTs sequenced from the cDNA library were highly
similar to ovgal11, a previously uncharacterized member of the
galectin family of secreted animal lectins (16). OVGAL11 was
originally shown to be induced in gastrointestinal tissue and
secreted into the intestinal lumen in response to inflamma-
tion and eosinophil infiltration after infection of sheep with
the helminth Haemonchus contortus (16). The sequence of
OVGAL11 protein displayed highest similarity to human
galectin-10 (also known as Charcot–Leyden crystal protein) (17,
18) and human galectin-13 (also known as placental protein-13
or PP13) (19). Galectins are proteins with a conserved carbo-
hydrate recognition domain (CRD) that bind -galactosides,
thereby cross-linking glycoproteins as well as glycolipid recep-
tors on the surface of cells and initiating biological responses (20,
21). Functional studies on the extracellular and intracellular
roles of galectins have implicated them in cell growth, differen-
tiation, and apoptosis, in addition to cell adhesion, chemoat-
traction, and migration. Because OVGAL11 from the intestine
and endometrium of sheep does not have a known orthologue,
it is proposed to be a new family member and renamed galectin-
15. Of particular interest is the fact that galectin-15 appears to
be the long-sought-after Mr 14,000 (14K) protein from sheep
endometrium initially characterized as a progesterone-
modulated protein associated with crystalline-inclusion bodies in
uterine epithelia and conceptus trophectoderm (Tr) (22).
Methods
Animals. Experimental and surgical procedures on crossbred
Suffolk sheep (Ovis aries) complied with the Guide for Care and
Use of Agriculture Animals and were approved by the Institu-
tional Animal Care and Use Committees of Texas A&M Uni-
versity.
In study 1, cyclic ewes were mated at estrus (day 0) to either
a vasectomized or an intact ram and were hysterectomized (n 
5 sheep per day) on days 10, 12, 14, or 16 of the estrous cycle or
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on days 10, 12, 14, 16, 18, or 20 of pregnancy (gestation period
is 147 days). On days 10–16, the uterine lumen was flushed with
saline and examined for the presence of a morphologically
normal conceptus to confirm pregnancy. Flushes were not
possible on days 18 or 20, because the conceptus firmly adheres
to the endometrial luminal epithelium (LE) and basal lamina.
Cross sections of the uterine horn ipsilateral to the ovary bearing
the corpus luteum were fixed in 4% paraformaldehyde in PBS for
24 h, dehydrated in 70% ethanol, and then embedded in
Paraplast-Plus (Oxford Labware, St. Louis). The remaining
endometrial tissues were dissected from myometrium and frozen
at 80°C. Uterine flushes were clarified by centrifugation
(3,000  g for 30 min at 4°C) and frozen at 80°C.
In study 2, cyclic ewes (n  20) were checked daily for estrus
and then ovariectomized and fitted with indwelling uterine
catheters on day 5 as described (23). Sheep were then assigned
randomly (n  5 per treatment) to receive daily i.m. injections
of progesterone andor a progesterone receptor (PR) antagonist
(ZK 136,317; Schering) and intrauterine infusions of control
serum proteins andor recombinant ovine IFN (oIFN)- protein
as follows: (i) 50 mg of progesterone (P, days 5–16) and 200 g
of control (CX) serum proteins (days 11–16) (PCX); (ii) P and
75 mg of ZK 136,317 (days 11–16) and CX proteins
(PZKCX); (iii) P and IFN- (2  107 antiviral units, days
11–16) (PIFN); or (iv) P and ZK and IFN- (PZKIFN).
Steroids were administered daily in corn oil vehicle. Both uterine
horns of each ewe received twice-daily injections of either CX
proteins (50 g per horn per injection) or IFN- (5  106
antiviral units per horn per injection). Recombinant oIFN- was
produced in Pichia pastoris and purified as described (24).
Proteins were prepared for intrauterine injection as described
(23). This regimen of progesterone and recombinant oIFN-
mimics the effects of progesterone and the conceptus on endo-
metrial expression of hormone receptors and IFN- -stimulated
genes during early pregnancy in ewes (25–27). All ewes were
hysterectomized on day 17, and the uterus and endometrium
were processed as described in study 1.
In study 3, uterine secretions, termed uterine milk, were
collected from the nongravid uterine horn of unilateral pregnant
sheep (n  4) on day 80 of pregnancy by flushing the uterine
horn with 100 ml of saline by using methods described initially
by Bazer et al. (28). The uterine flushing was clarified by
centrifugation and stored at 80°C.
RNA Analysis. Total cellular RNA was isolated from frozen
endometrial tissue by using TRIzol reagent (GIBCOBRL).
Steady-state levels of galectin-15 mRNA were assessed in the
endometrium from Studies One and Two by slot-blot hybridiza-
tion as described (29). A radiolabeled antisense cRNA probe was
generated from a linearized ovine endometrial galectin-15
cDNA by in vitro transcription with [-32P]UTP and hybridized
with denatured endometrial total RNA (20 g) from each ewe
affixed to a slot-blot membrane. To correct for variation in total
RNA loading, a duplicate total endometrial RNA slot-blot
membrane was hybridized with a radiolabeled antisense 18S
rRNA cRNA (pT718S; Ambion, Austin, TX). After washing, the
blots were digested with ribonuclease A. The radioactivity
associated with each slot was quantified by using a Typhoon 8600
MultiImager (Molecular Dynamics) and is expressed as relative
units.
In Situ Hybridization Analysis. Galectin-15 mRNA was localized in
uterine tissue sections (5 m) by in situ hybridization analysis as
described (29). Deparaffinized, rehydrated, and deproteinated
uterine tissue sections were hybridized with radiolabeled anti-
sense or sense galectin-15 cRNA probes generated by in vitro
transcription with 5-[-[35S]thio]UTP. After hybridization,
washing, and ribonuclease A digestion, slides were dipped in
NTB-2 liquid photographic emulsion (Kodak), stored at 4°C for
1 week, and developed in D-19 developer. Sections were then
counterstained with Harris-modified hematoxylin (Fisher Sci-
entific), and protected with a coverslip.
Immunohistochemistry. Immunoreactive galectin-15 protein was
detected in uterine tissue cross sections from study 1 with rabbit
anti-OVGAL11 polyclonal antibody (16) at a 1:2,000 dilution
and a Super ABC Rabbit IgG Kit (Biomedia) by using methods
described (30). Antigen retrieval was performed by using Pro-
nase E digestion as described (31). Negative controls included
substitution of the primary antibody with purified rabbit IgG at
the same final concentration.
Western Blot Analyses. Uterine flushes from study 1 were con-
centrated by using Centricon-3 columns (Amicon). Protein
content of concentrated flushes (study 1) and uterine milk (study
3) was determined by using a Bradford protein assay (Bio-Rad)
with BSA as the standard. Proteins were denatured and sepa-
rated by SDS15% PAGE, and Western blots were conducted as
described (30) by using enhanced chemiluminescence detection.
Immunoreactive galectin-15 was detected by using the rabbit
anti-ovine OVGAL11 antibody (16) at a 1:10,000 dilution.
Negative control blots were performed in which primary anti-
body was replaced by rabbit IgG at the same concentration.
Carbohydrate Binding Analysis. This analysis was a modified ver-
sion of methods for the in vitro analysis of saccharide binding by
galectin-10 (32). All binding experiments were performed in
Dulbecco’s PBS (Sigma). Briefly, uterine flush proteins from
day-16 pregnant ewes (200 g) were incubated overnight at 4°C
with a 50-l bed volume of lactose-conjugated agarose (Sigma).
For competition, lactose, mannose, or fucose (Sigma) was added
at a final concentration of 500 mM. After incubation, the resin
was washed three times in 1 ml of PBS, and the bound protein
was eluted with SDSPAGE-reducing sample buffer. The rela-
tive amount of galectin-15 protein bound to lactose was deter-
mined by SDS15% PAGE and Western blot analysis using the
rabbit anti-ovine OVGAL11 antibody.
Immunoprecipitation. Proteins (40 g) from uterine flushings
from day-16 pregnant ewes (study 1) or uterine milk (study 3)
were incubated overnight at 4°C with 1l of normal rabbit serum
(Sigma), rabbit anti-OVGAL11 antibody (16), or rabbit anti-
ovine trophoblast protein 1 (oTP-1oIFN-) (33) (kindly pro-
vided by James D. Godkin, University of Tennessee, Knoxville)
and 10 l of protein AG plus-agarose (Santa Cruz Biotechnol-
ogy) in immunoprecipitation lysis buffer (30). Proteins bound to
the washed beads were separated on an SDS8–16% PAGE
gradient gel (Bio-Rad) and detected by Western blot analysis.
Antibodies used in the analyses were rabbit anti-OVGAL11
(1:10,000) or rabbit anti-oTP-1oIFN- (1:1,000). As a positive
control, each gel contained 5 g of total protein from a day-16
pregnant uterine flush and from uterine milk.
Statistical Analyses. Data from slot-blot hybridization and protein
slot-blot analyses were subjected to least-squares analysis of
variance by using the General Linear Models procedures of the
Statistical Analysis System (SAS Institute, Cary, NC). Slot-blot
hybridization data were corrected for differences in sample
loading by using the 18S rRNA data as a covariate. Data from
study 1 were analyzed for effects of day, pregnancy status (cyclic
or pregnant), and their interaction. Data from study 2 were
analyzed by using preplanned orthogonal contrasts (PCX
versus PIFN, PCX versus PZKCX, and PIFN versus
PZKIFN). Data are presented as the least-squares means
with overall SE.









During the course of sequencing ESTs from a day-14 pregnant
ovine endometrial cDNA library, 1% of the 5,000 sequences
were determined to be highly similar (95% identity) to OV-
GAL11 (GenBank accession no. AF252548) (16). Based on the
nucleotide sequence of the coding region (414 nt), ovine endo-
metrial galectin is composed of 137 aa predicted to yield a
15.4-kDa protein with a pI of 5.24. It displayed the greatest
similarityidentity to human galectin-13 (44% identity) fol-
lowed by human galectin-10 (40% identity) (Fig. 1). Subse-
quent FASTA searches against human, mouse, and rat genome
sequences detected no other similar genes or proteins. Given
that it has no known orthologue, OVGAL11 from sheep intes-
tine and endometrium is considered a previously uncharacter-
ized galectin family member and named galectin-15.
The amino acid sequence of endometrial galectin-15 was
searched for conserved domains, which revealed the presence of
a CRD characteristic of galectins (34). The CRD is a consensus
motif that consists of 13 aa (35), of which 8 (H-N-R-------V-
N------W--E-R) play a critical role in sugar binding (32, 36).
Comparison of the galectin-15 CRD with the conserved CRD of
other galectins indicates that four residues are identical (V62,
N64, W71, and E74) and two are conservatively substituted (R53
and K76). The C57 is different from prototypical galectins but
appears to allow for binding of mannose in galectin-10 (37).
Consistent with other galectins, galectin-15 had no apparent or
predicted signal peptide, transmembrane domain, or glycosyla-
tion sites. A PROSITE search revealed two putative cell attach-
ment sequences at positions 123 (LDV) and 126 (RGD) that are
conserved integrin-binding domains (38).
Northern blot analysis of total RNA from endometria of cyclic
and pregnant ewes detected a single transcript of 0.8 kb (data
not shown). Steady-state levels of galectin-15 mRNA were very
low on day 10 and then increased 13-fold between days 10 and
14 in both cyclic and pregnant ewes (Fig. 2A). However, galec-
tin-15 mRNA levels decreased between days 14 and 16 in cyclic
ewes but increased in pregnant ewes (day  status, P  0.001).
Galectin-15 mRNA levels in endometrium of day-16 pregnant
ewes were 7-fold greater than for day-16 cyclic ewes. In
pregnant ewes, galectin-15 mRNA levels declined between
days 16 and 18 of pregnancy but remained detectable to at least
day 20.
Galectin-15 mRNA was specifically expressed in endometrial
LE and superficial ductal glandular epithelium (sGE) in both
cyclic and pregnant ewes (Fig. 2B). In cyclic ewes, expression of
galectin-15 mRNA was low in endometrial LE and sGE of cyclic
ewes on day 10, increased to day 14, and then markedly de-
creased on day 16. Galectin-15 mRNA was not detected in the
endometrium on days 1, 3, 5, 7, or 9 of the estrous cycle (data not
shown). In pregnant ewes, galectin-15 mRNA was very low or
undetectable in endometrial LE and sGE on day 10 and in-
creased between days 10 and 16 (Fig. 2B). Galectin-15 mRNA
expression was abundant in endometrial LE and sGE on days 18
and 20 of pregnancy but was not detected in the conceptus.
Indeed, the decline in galectin-15 mRNA between days 16 and
20 of pregnancy is most likely due to ablation of LE by the
conceptus as binucleate cells form a syncytium with the LE,
which occurs as the conceptus elongates and attaches along the
length of the uterine horns (39). After syncytium formation with
the LE, the binucleate cells migrate and adhere to the epithelial
basement membrane.
Overall changes in immunoreactive galectin-15 protein abun-
dance in endometrial LEsGE paralleled changes in galectin-15
mRNA in cyclic and pregnant ewes (Fig. 3A). On days 10 and 12
Fig. 1. CLUSTALW alignment of the amino acid sequences of ovine galectin-15
with human galectin-10 and -13. The asterisks denote the conserved residues
forming the CRD found in prototypical galectin family members. The under-
lined amino acids indicate a predicted cell attachment sequence that is a
conserved integrin binding site.
Fig. 2. Galectin-15 mRNA expression in the uterus (study 1). (A) Steady-state
levels of galectin-15 mRNA in the endometrium as determined by slot-blot
hybridization analysis. (B) In situ hybridization analysis of galectin-15 mRNA in
the uterus. C, cyclic; D, day postestrusmating; P, pregnant; S, stroma. (Bar 
10 m.)
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of the cycle and pregnancy, galectin-15 protein was localized
primarily in the cytoplasm of epithelial cells. However, on days
14–20 of pregnancy, galectin-15 protein was readily apparent
near and on the apical surface of endometrial LE. Further,
galectin-15 protein was localized within discrete cytoplasmic
structures in the conceptus Tr on days 16, 18, and 20 of
pregnancy.
Western blot analyses of uterine flushings revealed a single
immunoreactive protein of 15 kDa (Fig. 3B), which is the
predicted size based on the inferred amino acid sequence and
similar to OVGAL11 in sheep intestine (16). Galectin-15 protein
levels were low in the uterine lumen of cyclic ewes on days 10 and
12 of pregnancy but abundant in the uterine lumen on days 14
and 16, which corresponds to the onset of conceptus implanta-
tion and firm adherence of the Tr to LE (39).
The regulation of galectin-15 gene expression in the endome-
trium by progesterone and oIFN- was determined in study 2
(Fig. 4). In ewes receiving intrauterine injections of CX proteins,
progesterone increased galectin-15 mRNA in the endometrium
(PCX vs. PZKCX, P  0.01). In progesterone-treated
ewes, intrauterine injections of recombinant oIFN- increased
galectin-15 mRNA levels4-fold (PCX vs. PIFN, P 0.03).
However, this effect of IFN- depended on progesterone
(PZKCX vs. PZKIFN, P  0.10). Galectin-15 mRNA
was detected in LE and sGE of endometria from PCX and
PIFN ewes (Fig. 4B); however, it was not detected in ewes
receiving the ZK 136,317 PR antagonist, regardless of intrauter-
ine protein treatment.
The carbohydrate-binding ability of ovine endometrial galec-
tin-15 was assessed by using lactose-agarose (Fig. 5A). Galec-
tin-15 from day-16 pregnant uterine flushes bound lactose (lane
1), and this binding could be partially blocked by competition
with free lactose (lane 2), mannose (lane 3), or fucose (lane 4).
Specific binding of galectin-15 from uterine flushes and uterine
milk was also detected by using mannose-agarose and fetuin-
agarose (data not shown).
The homology of galectin-15 to galectin-10, also known as
Charcot–Leyden crystal protein in eosinophils and basophils
(40), and its apparent molecular weight suggested that galec-
tin-15 may be the 14K endometrial protein initially characterized
as a progesterone-modulated, low-molecular-weight protein
from the sheep uterus associated with crystalline inclusion
bodies in uterine epithelia and conceptus Tr (22). The 14K
protein was originally identified as a contaminant of native
oTP-1oIFN- protein that was purified from conceptus cultures
and used to generate antiserum in rabbits (22). Galectin-15 from
uterine flushes of day-16 pregnant ewes and from uterine milk
(study 3) was immunoprecipitated with rabbit antiserum to
oTP-1oIFN- (Fig. 5 B and C). In the uterine flushing from a
day-16 pregnant ewe, the rabbit anti-oTP-1oIFN- antibody
recognized two immunoreactive proteins that are oTP-1oIFN-
(19 kDa) and galectin-15 (15 kDa). Only galectin-15 is present
in uterine milk, because oTP-1oIFN- is produced only by the
mononuclear trophectodermal cells of the ovine conceptus
between days 10 and 21–25 of gestation.
Discussion
Temporal changes in expression of endometrial galectin-15
mRNA support the hypothesis that ovarian progesterone and
conceptus IFN- regulate transcription of the galectin-15 gene
(Fig. 2 A). The increase in galectin-15 mRNA in LE and sGE
after day 10 postestrusmating is coincident with the disappear-
ance of PR mRNA and protein in the same epithelia (31).
Similarly, the decrease in galectin-15 mRNA between days 14
and 16 of the cycle is coincident with the reappearance of PR
protein in endometrial LE and a decline in circulating proges-
terone. Galectin-15 mRNA was induced in endometrial LE and
sGE of ovariectomized ewes treated with progesterone for 12
days (Fig. 4), but this induction was prevented by the PR
antagonist ZK 136,317. Continuous exposure of the sheep uterus
to progesterone for 8–10 days down-regulates PR expression in
endometrial LE and sGE but not stroma or myometrium (25).
PR is present in the endometrial epithelia of PZK-treated
sheep (41), because PR antagonists prevent the inhibitory effects
of progesterone on the PR gene expression. These results
Fig. 3. Galectin-15 protein in the endometrium and lumen of the uterus
(study 1). (A) Immunohistochemical localization of galectin-15 protein in the
endometrium. Sections were not counterstained. (B) Western blot analysis of
proteins in the lumen of the uterus. C, cyclic; D, day postestrusmating; P,
pregnant; S, stroma. (Bar  10 m.)
Fig. 4. Effects of progesterone and IFN- on galectin-15 mRNA in the uterus
(study 2). (A) Steady-state levels of galectin-15 mRNA in the endometrium as
determined by slot-blot hybridization analysis. (B) In situ hybridization local-
ization of galectin-15 mRNA in the endometrium. S, stroma. (Bar  10 m.)








support the hypothesis that progesterone binds to PR, which
represses or silences transcription of the galectin-15 gene in the
endometrial LEsGE before day 10. Consequently, the proges-
terone modulation of galectin-15 mRNA may be attributed, at
least in part, to down-regulation of the PR by progesterone that
occurs in the LE and sGE between days 10 and 12 of the cycle
and pregnancy. Thus, PR loss in the endometrial epithelia may
reprogram these cells, allowing them to express genes associated
with terminal differentiated function (42).
Galectin-15 is also an IFN--stimulated gene. IFN- is the
pregnancy recognition hormone in sheep that acts on the
endometrium to prevent development of the luteolytic mecha-
nism, thereby maintaining the corpus luteum and production of
progesterone (42). The increase in galectin-15 expression in
endometrial LE and sGE between days 12 and 16 of early
pregnancy parallels the increase in production of IFN- by the
conceptus, which is maximal between days 14 and 16 (43).
Intrauterine administration of IFN- increased galectin-15
mRNA, but only in progesterone-treated ewes (Fig. 3). One
hypothesis is that IFN- can only stimulate transcription of the
galectin-15 gene in the absence of repression by liganded PR.
Alternatively, the PR-positive stroma may produce a ‘‘proges-
tamedin’’ that is required for the LE to respond to IFN- (42).
The signaling pathway whereby IFN- regulates transcription of
the galectin-15 gene is not known, but it certainly does not
involve the classical Janus kinasesignal transducer and activator
of transcription signaling pathway (26, 44). To date, Wnt7a is the
only other gene identified in endometrial LE that is increased by
IFN- (26).
These studies identified galectin-15 as the previously unchar-
acterized 14K progesterone-modulated protein from the sheep
uterus associated with crystalline inclusion bodies in endome-
trial LE and conceptus Tr (22). The 14K protein was originally
identified as a component of conceptus-conditioned culture
medium and uterine flushes (45). Release of the 14K protein was
attributed to the cellular breakdown of concepti in culture (22).
The 14K protein was confined to the endometrial LE and sGE
but absent from the deep GE in the uteri of day-16 pregnant
sheep and from sheep treated with progesterone for 14 or 30 days
(22). In the uterine epithelia, immunoreactive 14K protein was
most strongly detected over crystal-like structures but was also
uniformly present over the cytoplasm and nucleoplasm (22).
Immunogold electron microscopy revealed that within Tr, the
14K protein was localized to large, membrane-bound rhomboi-
dal or needle-shaped crystal structures but not in the endoplas-
mic reticulum and Golgi body. Thus, Kazemi and coworkers (22)
suggested that the protein was secreted by the endometrial
epithelia and taken up by the conceptus from uterine histotroph.
Interestingly, development of in vitro-produced bovine blasto-
cysts transferred into the sheep uterus resulted in the presence
of crystals in Tr cells (46). The presence of crystals in sheep
uterine milk (or histotroph) present between maternal and fetal
intercotyledonary membranes is well documented (47, 48).
Reports of crystals in sheep Tr and uterine epithelia are nu-
merous (48). Similar progesterone-induced crystal proteins are
present in endometrium and conceptus Tr of many mammals,
including rabbit, mouse, pig, and human (49–53). Accordingly,
galectin-15-related family members are likely to be expressed in
the endometrium of many mammals to facilitate conceptus–
endometrium interactions. Although the biological role(s) of
galectin-15 crystals in the conceptus is not known, the intracel-
lular role of other galectins includes modulation of cell growth,
differentiation, and apoptosis through functioning as pre-mRNA
splicing factors and interacting with specific intracellular ligands
such as Ras and Bcl-2 (53, 54).
Galectin-15 is the newest member of the multifunctional
galectin family. Members of this family must fulfill two key
criteria: (i) conserved sequence elements forming a CRD, and
(ii) binding affinity for -galactosides without requiring metal
ions for activity. These studies indicate that galectin-15 fulfills
the two key criteria to be considered a bona fide galectin family
member, because it contains the CRD and binds lactose and
mannose (Figs. 1 and 5). Although the CRD of galectin-15
differs slightly from that in the prototypical galectins, it does
possess the ‘‘jellyroll’’ structural fold similar to that of the
prototypical galectin-1 and -2 and found in galectin-10 and -13
(55), which share similarity with galectin-15. Galectins bind
-galactosides by means of the CRD, but the carbohydrate-
binding specificity for each galectin appears to be different
(56). In addition to the CRD, galectin-15 also contains pre-
dicted cell attachment sequences (LDV and RGD) that could
mediate binding to integrins in extracellular matrix proteins
(57, 58). Integrins are thought to be the dominant glycopro-
teins that regulate Tr adhesion to endometrial LE during
implantation (58, 59). During the periimplantation period of
pregnancy in sheep, integrin subunits v, 4, 5, 1, 3, and
5 are constitutively expressed on conceptus Tr and apical
surface of endometrial LE (60). In sheep, receptivity to
implantation does not appear to involve changes in temporal
or spatial patterns of integrin expression but may depend on
changes in expression of extracellular matrix proteins, which
are ligands for heterodimers of these integrins. Other galectins
bind integrins, fibronectin, and laminin, because these extra-
cellular matrix proteins are modified with -galactoside sugars
(20, 21). Functional studies of other galectins have implicated
these proteins in cell growth, differentiation, and apoptosis as
well as in cell adhesion, chemoattraction, and migration (20,
61, 62). The temporal and spatial alterations in galectin-15
mRNA and protein in endometrial LE and lumen of the ovine
uterus during pregnancy, combined with the functional aspects
Fig. 5. Biochemical characterization of ovine endometrial galectin-15. (A)
Carbohydrate-binding analysis of galectin-15 from the uterine lumen of
day-16 pregnant ewes by using lactose-agarose and competition with lactose,
mannose, or fucose. (B) Immunological identification of galectin-15 from the
uterine lumen of day-16 pregnant ewes (study 1) and as the previously
uncharacterized 14K protein. (C) Immunological identification of galectin-15
from uterine milk (study 3) as the 14K protein. The anti-oTP-1oIFN- antibody
crossreacts with the 14K protein (22), which is ovine endometrial galectin-15.
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of galectin-15 and its family members, make it a strong
candidate for a mediator of conceptus–endometrium interac-
tions during implantation. Therefore, the proposed extracel-
lular role of galectin-15 in the uterine lumen is to functionally
bind and cross-link -galactosides on glycoproteins, such as
integrins, fibronectin, and laminin, and glycolipids, thereby
allowing it to function as a heterophilic cell adhesion molecule
bridging the endometrial LE and conceptus Tr. The biological
responses of the Tr to galectin-15 may also include migration,
proliferation, and differentiation, which are critical for suc-
cessful conceptus implantation. Understanding the extracel-
lular and intracellular functions of galectin-15 in endometrial
epithelia and conceptus Tr will broaden our knowledge of the
roles of galectins in basic biological processes and facilitate
development of therapeutic applications for galectins in in-
fertility and cancer.
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